Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Khalid Shah

Khalid Shah

Associate Professor
Harvard Medical School
USA

Biography

Khalid Shah is an Associate Professor at Harvard Medical School and directs the Molecular Neurotherapy and Imaging Laboratory at Massachusetts General Hospital in Boston, MA. He is also the Director of the Stem Cell Therapeutics and Imaging program in MGH's Center for Translational Research, and is a Principal Faculty at Harvard Stem Cell Institute in Boston. Dr. Shah's recently published works are two books featuring current groundbreaking insights into stem cell therapies for cancer, Stem Cell Therapeutics for Cancer (Wiley-Blackwell 2013), and Mesenchymal Stem Cells in Cancer Therapy (Elsevier 2014). The potential of developing novel cancer therapies by him and his team has been recognized by many cancer alliances and associations. Based on this, he has received the young investigator award from Alliance for cancer gene therapy (ACGT), Research fellow award from American Cancer Society (ACS), Distinguished research award from Academy of Radiology and Innovation awards from James McDonnell Foundation, American Brain Tumor Association (ABTA) and Goldhirsh foundation. Additionally, Dr. Shah has participated in the training of numerous undergraduate, graduate students and residents at MGH and the potential of his mentoring has been recognized by Harvard Medical School, who recently awarded him the Harvard Young Mentor Award.

Research Interest

In recent years, Dr. Shah and his team have pioneered major developments in the cancer research field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology, validating the use of therapeutic stem cells alone and in combination with clinically approved drugs for cancer therapy.